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Abstract
Background: Systemic sclerosis (SSc) is a chronic disease characterized by autoimmunity, vasculopathy, and visceral
and cutaneous fibrosis. Vitamin D has several functions in the immunological system, and different studies have
suggested a potential role in triggering autoimmune diseases. Patients with SSc may present with low serum levels
of vitamin D, but the association between hypovitaminosis D and disease onset or any clinical manifestation is still
obscure. Our goal was to verify the causal relationship between hypovitaminosis D and SSc onset or any particular
clinical manifestation in the literature.
Methods: A systematic literature review was performed through February 24th, 2021 on Pubmed, Lilacs/BIREME,
and Cochrane databases. The eligible studies were read in full text, and, in the absence of exclusion criteria, were
included in this review after consensus between two reviewers.
Results: Forty articles met the eligibility criteria and the main results of each study are described. In most studies,
SSc patients showed a higher prevalence of vitamin D deficiency and insufficiency compared to controls.
Additionally, in some reports serum levels of vitamin D were inversely correlated with the severity of SSc. Oral
supplementation did not seem to affect serum levels of vitamin D. Four of the included studies were with
experimental models.
Conclusion: In conclusion, vitamin D deficiency seems to have a role in susceptibility to SSc, as well as in the
clinical manifestations of the disease.
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Introduction
Systemic sclerosis (SSc) is a multisystemic autoimmune
disease with a complex pathophysiology. SSc is charac-
terized by the presence of autoantibodies and arises from
the interrelation between vascular dysfunction, adaptive
and innate immunity dysregulation, and excess activa-
tion of fibroblasts and similar cells, resulting in the de-
velopment of progressive tissue fibrosis [1–3]. With a
multifactorial etiology, several environmental and gen-
etic factors seem to trigger the onset of SSc and its out-
comes [1]. SSc affects predominantly young adults and
has an important impact on quality of life and mortality
rates [4]. Treatment is multidisciplinary, with a focus on
symptoms management and predominant visceral injur-
ies. A better understanding of the pathophysiology be-
hind the disease could help advance research on this
area and allow for the development of new therapeutic
options [4].
Vitamin D is a steroid hormone known for its function
on the regulation of calcium homeostasis and bone me-
tabolism. The active metabolite of vitamin D (calcitriol)
is formed by the activation of a precursor on skin ex-
posed to ultraviolet B (UVB) radiation [5]. Serum
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vitamin D levels may vary according to factors such as
food intake (although to a lesser extent), bowel absorp-
tion, exposure to sunlight, and renal and hepatic metab-
olisms [5–7]. Vitamin D receptors (VDR) are present in
antigen-presenting cells, natural killer cells, and acti-
vated B- and T-cell lymphocytes [5], which reinforces
the evidence of its multiple immunomodulatory actions
on adaptive and innate immune responses [8]. Vita-
min D has a predominantly immunosuppressive effect,
inhibiting proinflammatory cytokines production (IL6
and IL-17), stimulating anti-inflammatory cytokines
production (IL4 and IL-10), and polarizing the Th1
response (IL-1, TNF-α, IFN-γ) into a Th2 response
(autoantibodies, TGF-β) [5, 6]. Additionally, vitamin
D inhibits the Th17 response and stimulates regula-
tory T cells. The immunomodulatory and tolerant ef-
fects of vitamin D on the adaptive and innate
immune systems seem to play a protective role in the
development of autoimmunity [6].
Hypovitaminosis D has been reported in several auto-
immune diseases. Serum vitamin D levels are signifi-
cantly lower in patients with SSc compared to healthy
individuals [6]. Some studies have reported vitamin D
insufficiency (< 30 ng/ml) in over 80% of patients with
SSc [9, 10], usually in association with worse quality of
life and lower bone mass [10–14]. The role of hypovita-
minosis D in SSc pathophysiology and its possible thera-
peutic impact have been the subject of various studies in
different scenarios. Therefore, this systematic review
aims to verify the causal relationship between hypovita-
minosis D and SSc onset or any particular clinical mani-
festation of the disease.
Methods
A comprehensive search in PubMed, Lilacs/BIREME,
and Cochrane Library databases was performed
through Fabruary 24th, 2021. The keywords used
were “systemic sclerosis” and “vitamin D”. No restric-
tions for language, year or type of publication were
added (Supplemental file 1).
After excluding duplicate studies, two reviewers inde-
pendently reviewed all the articles found in different da-
tabases. Initially, titles and summaries were analyzed
according to the eligibility criteria and all studies on the
association between serum vitamin D levels and the clin-
ical and pathophysiological aspects of SSc or on the role
of vitamin D in the pathophysiology of SSc were se-
lected. The selected articles were read in full and, in the
absence of exclusion criteria, were included in this re-
view after consensus between two reviewers. If no con-
sensus were reached, a third reviewer would decide on
study inclusion. The question that guided studies selec-
tion was: “What is the role of vitamin D in the patho-
physiology and in the clinical manifestations of SSc?”, so
all observation or intervention studies assessing vitamin
D levels and its correlation with clinical and/or patho-
physiological manifestations were eligible for inclusion
in this review. We included all clinical and experimental
studies published after peer-review, that would address
the question guiding paper selection. Articles describing
vitamin D levels on SSc patients without evaluation of
clinical and/or pathophysiological manifestations were
excluded, as well as other review articles and research
on SSc therapy or treatment. Preprint studies were not
included. In addition, the reference sections of the rele-
vant articles were scanned for additional references that
could have been missing from the databases.
Most of the studies included in this review defined
vitamin D deficiency as a serum level < 10 ng/ml and in-
sufficiency as a serum level of 10–30 ng/ml.
Results
Overall, 391 publications were identified in the different
databases: 162 in PubMed, 211 in Lilacs/BIREME, and
10 in Cochrane Library. Of these, 118 were excluded
after summary analysis, 205 were duplicate studies, two
were not available online, and one was an erratum. Add-
itionally, 17 publications were excluded after full text re-
view for not meeting the eligibility criteria, and 12 were
excluded due to being review articles. Eight additional
articles were included after reference review. At the end
of the selection process, 40 articles were included in this
systematic review. Four included studies were experi-
mental models on the effect of vitamin D or a vitamin D
analogue. These data are shown in the flowchart on
Fig. 1.
Fig. 1 Flowchart with the selection of articles for the
systematic review
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Characteristics of the selected articles, number of sub-
jects, serum levels of vitamin D, proportion of patients
with vitamin D < 10 and < 30 ng/mL and the main results
of each study are presented in Table 1. Most studies
showed vitamin D deficiency and insufficiency in SSc pa-
tients, regardless of season or oral vitamin D supplemen-
tation. Some studies identified association of vitamin D
levels with clinical and pathophysiological manifesta-
tions, such as an inverse correlation of vitamin D levels
with disease severity. Other reports did not identified an
association between SSc manifestations and vitamin D.
The methodology and the main results of the experi-
mental studies included in this review are summarized
in Table 2.
Discussion
In the last two decades, several authors have reported
lower levels of vitamin D in patients with SSc compared
to healthy individuals [11–14, 16, 21, 25, 38, 48]. Despite
the well-known seasonal variations in serum vitamin D
levels, with peak values in summer [41], SSc patients
present consistently lower levels throughout all seasons
[38, 41]. Initially, we intended to estimate the mean
serum vitamin D level among SSc patients across stud-
ies, but the great population heterogeneity could lead
this estimation to substantial misinterpretation and in-
accuracy. Seasonal variation, age, gender, comorbidities,
life habits and drug treatment were some of the factors
that could falsely impact this measure.
The evidence behind the association between hypovi-
taminosis D and SSc onset is scarce [15, 29–31, 34, 38].
So far, no published study has properly demonstrated
this cause-effect relationship. Future research needs to
add more on biologic plausibility, temporality, intensity,
consistency and dose-response effect of hypovitaminosis
D and SSc onset. An inception cohort study would be a
suitable design. However, it may not be feasible due to
the very low incidence of SSc in the general population.
Longitudinal case-control studies would be the alterna-
tive; nonetheless vitamin D levels may not be generally
available for comparison between groups.
Recently, An et al. (2017) have performed a meta-
analysis to investigate the association between vitamin D
and SSc, which included six case-control studies with a
total of 554 SSc patients and 321 healthy controls. Meta-
analysis results showed that SSc patients suffered from
decreased vitamin D levels compared with healthy con-
trols and in diffused SSc patients the vitamin D levels
were significantly lower than those in limited SSc.
Vitamin D level was not associated with Rodnan score,
systolic pulmonary pressure, gastrointestinal ulcer, or
pulmonary involvement, so the authors suggested that
lower vitamin D levels in SSc patients may not be a fac-
tor accelerating disease severity [49].
On the other hand, some studies have shown an asso-
ciation between vitamin D deficiency and severity of SSc
[9, 16, 41]. Hypovitaminosis D is common in SSc and
patients with vitamin D deficiency have a greater fre-
quency of pulmonary disease, lower diffusion and higher
estimated pulmonary hypertension compared to patients
with vitamin D insufficiency [8, 22, 37]. Additionally,
these patients have higher inflammatory markers [9, 22]
and Cruz-Domínguez et al. (2017) have demonstrated
lower vitamin D levels in patients with and without cal-
cinosis [24]. Park et al. (2017) demonstrated that vitamin
D deficiency is an independent risk factor for digital ul-
cers in SSc, suggesting an involvement with the micro-
angiopathic manifestations of the disease. However, the
study could not demonstrate an association with macro-
vascular conditions in SSc patients, such as arterial
stiffness and atherosclerosis [35], which suggests that
vitamin D may act differently on micro- and macrovas-
cular mechanisms in SSc. Caimmi et al. (2019) found in
a retrospective cohort study that a decrease in 25-hydro-
xyvitamin D (25(OH)D) is associated with the risk of
developing digital ulcers after 5 years [20]. In spite of
this, no consensus has been reached, and further stud-
ies are needed to clarify the association between low
vitamin D levels and the vascular involvement of the
disease [18, 21, 43, 49].
Hypovitaminosis D diagnosis is based on serum
25(OH) D levels, and there is no consensus regarding
the ideal values that should be adopted. Several experts
agree to define vitamin D deficiency as serum levels
below 10 ng/ml [9, 10, 16, 18, 22, 38]. However, this def-
inition is not universal, with some authors suggesting
deficiency levels to be lower than 20 ng/ml (50 nmol/l)
[39, 41], taking in consideration the regulatory variations
of PTH. In turn, vitamin D insufficiency is commonly
defined as serum levels between 10 and 30 ng/ml, with
levels > 30 ng/ml being considered sufficient [9, 22, 24,
27]. Higher levels of vitamin D do not seem to provide
any additional benefits [50]. Nevertheless, the optimal
concentration of vitamin D for proper immune system
function is not yet well-defined. Studies have demon-
strated that genetic polymorphisms in the vitamin D
binding protein, in enzymes or even in the VDR
could determine variations in 25(OH) D serum levels,
further complicating the definition of adequate serum
levels [51–53].
Vitamin D deficiency in patients with SSc seems to be
multifactorial. In a retrospective cohort comprising 327
SSc patients and 141 controls, Arnson et al. (2011) sub-
stantiate an inverse relation between serum vitamin D
levels and the extent of cutaneous involvement, they
showed that patients with a Rodnan score higher than
10 had a significantly lower serum vitamin D level com-
pared to other patients (17.7 ± 10.4 ng/ml versus 8 ±
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Table 1 Characteristics and results of the selected studies



















Serum Klotho and vitamin D lower in SSc patients (p < 0.001).
Higher intact PTH in SSc patients (p < 0.001).








Lower vitamin D levels in SSc patients (p < 0.001). Association
with lower DLCO (p < 0.02). Inverse association with skin extent
(mRSS> 10; p = 0.02) and RF expression (p < 0.001).








Lower vitamin D levels in SSc patients (p < 0.001). Association
with PTH (p = 0.001), osteocalcin (p < 0.05), deoxypyridinoline
(p < 0.05) and BMD on lumbar spine and femur (p < 0.05).








Lower vitamin D levels in SSc patients (p = 0.0003). Association
with skin extent (mRSS> 10; p = 0.02) and PASP> 35 mmHg
(p = 0.02). No association with subtype and autoantibodies.








No significantly difference in insufficiency or deficiency between
groups, regardless of disease duration, subtype and autoantibodies.








High PTH associated with vitamin D deficiency (p = 0.01),
calcinosis (p = 0.009), and acrosteolysis (p = 0.015). No significant
correlation between supplementation and vitamin D levels.
Caimmi et al., 2019 [20] Cohort (65) - - - Lower vitamin D levels in patients with incident DU in relation
to patients with no incident DU over 5 years (− 17.4 vs 13.0,
p = 0,018).








Lower vitamin D levels in SSc patients (p < 0.001). No association
with disease subtype, cutaneous ulcers, skin extent,
gastrointestinal and joint involvement.








Association with lung disease (p = 0.009),longer disease duration
(p = 0.026), lower DLCO (p = 0.014), and higher PASP (p = 0.037),
ESR (p = 0.001) and CRP (p = 0.004).








Anti-25(OH) D IgM antibodies more frequent in SSc patients
and in a higher level (p = 0.002). No correlation with severity,
other autoantibodies and target organ damage.








Lower vitamin D levels in patients, especially in diffuse
cutaneous SSc (p < 0.001). Negative correlation with mRSS
(p < 0.05). No association with any internal organ involvement.








Lower vitamin D levels in SSc patients with and without
calcinosis (19.1 vs. 13.1; p = 0.56).
Di Liberto et al., 2019 [25] Cross-sectional 22.1 ± 9.7 (45) - - - Low vitamin D levels in SSc patients. Similar percentage of
regulatory T-cells (Tregs) in SSc patients and control group, with
higher percentage in SSc patients taking cholecalciferol.
Impaired Tregs capability to suppress T cell proliferation in SSc
patients. Increase in IL-10 in vitro production of patients Tregs
after treatment with (1,25(OH)2D3).








No association with disease subtype, BMI, lung fibrosis, renal
involvement, GERD, digital ulcers, mRSS, autoantibodies and
therapy.








Lower vitamin D levels in not supplemented patients
(9.8 ± 4.1 vs. 26 ± 8.1; p < 0.0001), but only 15/49 (31%)
supplemented patients reached the normal range of vitamin D.








Positive correlation with DLCO (p = 0.019). Negative correlation
of vitamin D with diastolic dysfunction, digital contractures and
muscle weakness. No correlation with autoantibodies or skin
extent. Higher vitamin D levels in patients with usual
supplementation (25.5%), but the difference between groups
failed to reach statistical significance (p = 0.488).








Lower vitamin D levels in SSc patients (p = 0.001). Inverse
correlationwith mRSS. No correlation with age, disease duration,
autoantibodies, digital ulcers, or systemic involvement.








Serum ET-1 higher in SSc patients (p = 0.001). Serum α-Klotho
and vitamin D lower in SSc patients (p = 0.001). Association of
vitamin D with gastrointestinal involvement on Medsger
severity scale (p = 0.003).
Hax et al., 2020 [30] Cross-sectional 23.9 ± 8.5 (50) 30.2 ± 6.2 (35) 2 (4%) 36 (72%) Lower vitamin D levels in SSc patients compared to control
group and lower vitamin D levels in SSc patients not taking
vitamin D supplementation. No associations between vitamin
D and cytokine levels or between vitamind D levels and
disease duration.








Lower vitamin D levels in SSc patients (p = 0.001). Association
with number of painful (p = 0.006) and swollen joints (p = 0.013)
and anti-Scl70 (p = 0.027). Association of vitamin D with BMD
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10.1 ng/ml; p = 0.02) [16], a result recently replicated in
another study [17]. Since then, other authors also dem-
onstrated an inverse correlation between serum vitamin
D levels and the extent of cutaneous involvement [11,
12, 28, 42]. On the other hand, some studies did not evi-
dence the same correlation between cutaneous involve-
ment and vitamin D levels [8, 26, 32, 35, 40, 49]. These
authors suggest that the epidermal synthesis could
Table 1 Characteristics and results of the selected studies (Continued)











on lumbar spine (p = 0.002) and femoral neck (p = 0.032).








No association between VDR polymorphisms (ApaI and TaqI)
and SSc susceptibility. Significant association between ApaI and
diffuse cutaneous SSc.








Hypovitaminosis D common in SSc patients and healthy
controls. No correlation with skin extent.








Association with a worse physical component on SF-36 and
physical function (p < 0.04). No association with gastrointestinal,
kidney and cardiopulmonary involvement.








Lower vitamin D levels in different autoimmune diseases
(SSc, SLE, PM, DM, APS, and RA).








Association with digital ulcers (p = 0.012). No association with
arterial stiffness, atherosclerosis, autoantibodies, mRSS, lung
disease, PASP, ESR and CRP.








No significant vitamin D correlation with PASP or lung fibrosis.
Hypovitaminosis D was common, despite 60.4% of patients
were taking usual supplementation.








Association of vitamin D with calcinosis (p < 0.034), heart
involvement (p < 0.012), DLCO (p < 0.006) and positive ANA
(p < 0.017). Hypovitaminosis D was common, despite 58.9% of
patients were taking usual supplementation. Vitamin D
deficiency was not different between groups (52% vs. 66.7%).








Vitamin D positive correlation with anti-Scl70 (p = 0.039) and
some SF-36 domains (vitality, social function, emotional role
and mental health). Negative correlation with HAQ-reach and
HAQ-grip strength. Positive correlation of vitamin D with BMI
(p = 0.038) and femur BMD (p = 0.037).








Seasonal variation in patients and controls (highest values in
summer, p < 0.01). Significantly lower levels in SSc patients in
all seasons.








Lower vitamin D levels in juvenile SSc patients (p = 0.04).
Positive correlation with femur BMD (p = 0.02).




Lower serum vitamin D levels in SSc patients (p = 0.02). No
correlation with mRSS.








Association of vitamin D with pulmonary fibrotic changes
(p = 0.04). Correlation with some domains of Medsger severity
scale (peripheral vascular, renal and gastrointestinal involvement).
Vitamin D levels not influenced by usual supplementation
(p = 0.81).








Inverse correlation with mRSS (p = 0.03) and subclinical liver
fibrosis (evaluated using the aspartate aminotransferase-to-
platelet ratio index; p = 0.02). No correlation with age and
disease duration.








Association of vitamin D with higher PASP (p = 0.004), lung
fibrosis (p = 0.04), anticentromere (p = 0.04) and ESR (p = 0.008).
No association with calcinosis, HAQ, or Medsger severity score.
Negative correlation with EDAS (p = 0.04). Vitamin D levels not
influenced by usual supplementation (p = 0.1).








Lower vitamin D levels in SSc patients (p < 0.001). More
frequent lung involvement, but without significance (p = 0.08).
No difference in joint involvement, autoantibodies, ESR and CRP.
Abbreviations: ANA antinuclear antibodies, APS antiphospholipid syndrome, BMD bone mineral density, BMI body mass index, CRP C-reactive protein, DLCO diffusion capacity of
carbon monoxide, DM dermatomyositis, DU digital ulcers, EDAS European Disease Activity Score, ESR erythrocyte sedimentation rate, ET-1 Endotelina 1, GERD gastroesophageal
reflux disease, HAQ Health Assessment Questionnaire, mRSS modified Rodnan skin score, OA osteoarthritis, PASP pulmonary arterial systolic pressure on Doppler
echocardiography, PM polymyositis, RA rheumatoid arthritis, RF rheumatoid factor, SF-36 Short-Form-36 Questionnaire, SLE systemic lupus erythematosus, SSc systemic sclerosis,
TGF-β transforming growth factor β, VDR vitamin D receptor
* Data are presented as mean ± standard deviation, except when indicated otherwise
aThese author presented only the proportion of patients with 25(0H) D < 12 ng/ml
bMedian (25–75th percentile)
cMedian ± IQR
dVitamin D levels only in non-supplemented patients (91/140)
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remain virtually normal, and that the hepatic and renal
hydroxylation mechanisms of vitamin D could also work
normally in this disease. Gastrointestinal involvement in
SSc seems to contribute to vitamin D malabsorption,
although these data are still controversial [19, 22]. Fur-
thermore, it is possible that some medications used by
SSc patients, such as corticosteroids or anticonvulsants
for neuropathic pain control, could interfere with vita-
min absorption [16]. In spite of this, not all authors were
able to evidence differences in vitamin D levels between
patients on and off these medications [41]. In addition
to the cutaneous and gastrointestinal involvement,
reduced sun exposure due to physical incapacity, self-
image disorders, depression, and social and psycho-
logical limitations could compound the deficit [9, 34].
As one might expect, serum vitamin D levels could sim-
ply reflect a better health in general due to better life
habits, such as exercise, outdoor activities and a health-
ier diet. This hypothesis is corroborated by previous re-
search showing an association between low levels of
25(OH) D and a worse quality of life and physical func-
tion in SSc patients [10, 33].
Many authors have explored the association between
lower vitamin D levels and SSc phenotype. Sampaio-
Barros et al. (2016) demonstrated an association between
lower serum vitamin D levels, underlying vascular in-
volvement and the production of anti-Scl70 autoanti-
bodies [10]. In addition, lower levels of vitamin D were
described in patients with diffuse cutaneous SSc when
compared with limited cutaneous disease [12, 49]. On
the other hand, Vacca et al. (2009) showed an associ-
ation between lower serum vitamin D levels and the
presence of anti-centromere autoantibodies [9]. Other
authors, however, have failed to demonstrate any associ-
ation between serum vitamin D levels and disease sub-
type or specific autoantibodies [18, 43]. Therefore, the
role of vitamin D in the clinical and serological pheno-
types of SSc is not yet well known. Further studies
should seek to clarify the possible associations between
hypovitaminosis D and disease subtype, also considering
the prognostic impact of these findings.
Considering the pathogenesis of SSc, several studies
have suggested that vitamin D is related to the regula-
tion of cellular immunity mechanisms [6–8]. The
synthesis of 1,25 dihydroxyvitamin D (1,25(OH)2D) and
presence of VDR in activated immune cells have
attracted the attention of several researchers. Vitamin D
acts as a regulator of innate and adaptive immune re-
sponses, promoting monocyte differentiation into mac-
rophages, modulating macrophage response and
inhibiting production of chemokines and inflammatory
cytokines [54]. Polymorphisms in the VDR gene also
seem to be associated with vitamin D deficiency, as sug-
gested by Kamal et al. (2016). The authors found no as-
sociation between VDR polymorphisms (ApaI and TaqI)
and susceptibility to SSc, but reported an association be-
tween the ApaI polymorphism and disease subtype [31].
In a recent study, an association between some VDR sin-
gle nucleotide polymorphisms and SSc susceptibility was
stablished [55].
Interestingly, Carmel et al. (2015) reported a higher
frequency and an increased level of anti-25(OH) D IgM
antibodies in SSc patients when compared to controls,
similarly to what has been described in patients with sys-
temic lupus erythematosus (SLE). However, the same
study reported lower levels of anti-25(OH) D IgG anti-
bodies in SSc patients than in controls [23]. The patho-
physiological significance and clinical relevance of these
autoantibodies in SSc remains controversial.
Vitamin D also seems to have an important role in
modulating TGF-β activity, an essential factor in colla-
gen production by fibroblasts. Zerr et al. (2015) analyzed
VDR expression in fibroblasts of SSc patients and in a
murine model of bleomycin-induced fibrosis. The au-
thors characterized the VDR as a negative regulator of
TGF-β signaling. Furthermore, they demonstrated that
treatment with a vitamin D analogue (paricalcitol) was
able to restore VDR signaling and reduce the pro-
Table 2 Characteristics and results of the selected experimental models of systemic sclerosis
Author Year Research Design Main results
Slominski
et al. [44]
2013 Culture of skin fibroblasts from
patients and controls
Efficacy of vitamin D in inhibiting TGF-induced collagen synthesis and inhibiting cell prolifera-




2015 Experimental model Effect of vitamin D analogue on periostin expression in fibroblasts and bleomycin-induced




2014 Cutaneous fibrosis in animal
model
Effect of the topical analogue of vitamin D (calcipotriol) on cytokines and the development of
fibrosis in rats with bleomycin-induced sclerosis; calcipotriol overexpressed Th2 axis expres-
sion, with antifibrotic effect.
Zerr et al.
[47]
2014 Culture of skin fibroblasts from
patients and controls
Expression of VDR in experimental model and fibroblasts; effect of paricalcitol on bleomycin-
induced fibrosis model and overexpression of TGF-β receptor (TBRICA); VDR characterization
as a negative regulator of TGF-β / Smad pathway signaling.
Abbreviations: TGF-β transforming growth factor β, VDR Vitamin D receptor
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fibrotic effects of TGF-β on fibroblasts [47]. Similar find-
ings were described in a study on skin fibroblast cultures
from SSc patients and controls, which demonstrated the
inhibitory effects of vitamin D in collagen and hyaluron-
ate production induced by TGF [44]. The research of
Boelsma et al. (1995) supports these findings by demon-
strating evidence of cutaneous fibrosis in humans, which
was also correlated with lower serum levels of vitamin D
[56]. However, this finding could also result from re-
duced vitamin D production due to cutaneous fibrosis
[57]. When assessing the therapeutic use of topical vita-
min D analogues on SSc patients with hypovitaminosis
D, a reduction in cutaneous fibrosis was observed. These
results may be due to the role of vitamin D in reducing
pro-fibrotic signaling by TGF-β and in inducing a
polarization of the local immune response by producing
potentially pro-fibrotic Th2 cytokines [45, 46]. A study
by Ahmadi et al. (2017) analyzed the serum levels of
fibroblast growth factor 23 (FGF-23), which has an es-
sential role in the kidney-bone axis, and its membrane
co-receptor Klotho. Klotho is a protein predominantly
expressed in the renal tubules and possibly involved in
calcium and phosphate homeostasis, prevents hyperpho-
sphatemia, fibrosis, arteriosclerosis and inflammation
[15]. A deficiency in α-Klotho expression has been stud-
ied for its potential involvement in endothelial dysfunc-
tion, microangiopathy, calcinosis and fibrosis, which are
common features of scleroderma. Serum levels of soluble
Klotho tend to decrease with age, and a defect in its
gene increases the risk for age-related diseases. Signifi-
cantly lower serum levels of Klotho in SSc patients were
identified [29]. It is believe that an increase in inflamma-
tory markers could reduce the renal expression of this
protein [15].
In two independent European cohorts, Vacca et al.
(2011) assessed the frequency of vitamin D insufficiency
and deficiency in SSc patients. These studies found no
difference in serum levels between SSc patients under
the standard dose of vitamin D supplementation (800
IU/day) or under placebo [58]. In a Spanish retrospective
cohort, Rios-Fernández et al. (2010) also described a
high prevalence of vitamin D deficiency in SSc patients
and corroborated the finding that supplementation with
the usual dose of vitamin D was insufficient (60.4% of
patients with low vitamin D levels were taking supple-
ments) [36]. Therefore, conventional vitamin D supple-
mentation (800 IU/day) does not seem to correct
deficiency in SSc patients. Higher doses could be needed,
especially in patients with severe disease or high inflam-
matory activity.
In a cross-sectional study with 140 SSc patients, 91 pa-
tients did not receive vitamin D supplementation, while
49 received 8000 to 12,500 IU of 25(OH) D weekly for a
minimum period of 6 months. Non-supplemented
patients had lower serum levels of vitamin D (9.8 ± 4.1
vs. 26 ± 8.1 ng/ml, p < 0.0001), although less than one-
third of supplemented patients had reached normal
levels by the end of the study [27]. In contrast, a retro-
spective cohort by Trombetta et al. (2017) was not able
to demonstrate any changes on serum vitamin D levels
in SSc patients supplemented with 1000 IU/day of chole-
calciferol for 6 to 12months [41]. The authors raised
several hypotheses to justify these findings, with the
strongest ones pointing to an interference in vitamin D
activation caused by cutaneous fibrosis and to cholecal-
ciferol malabsorption [27]. In spite of the variation in re-
sults for studies on vitamin D supplementation and the
need for further research, most experts still recommend
correcting vitamin D deficiency. The dose required to
achieve and maintain adequate 25(OH) D levels depends
on several factors. Some authors have suggested that a
raise of 1 ng/ml of 25(OH) D in serum levels would
require about 100 IU/day of vitamin D intake for ap-
proximately 3 months to reach a steady state once sup-
plementation is initiated [59, 60]. In spite of this
estimate, individual responses can vary, and the known
risk factors for vitamin D deficiency should be consid-
ered for a personalized therapeutic approach.
Our study has some limitations. The major one is the
lack of prospective cohort studies or randomized con-
trolled trials assessing the role of vitamin D in the
pathophysiology and in the clinical manifestations of
SSc, so no definitive conclusions could be drawn regard-
ing cause-effect relationship between hypovitaminosis D
and SSc onset or any clinical manifestation. Besides, lit-
erature on Medline/EMBASE was not included in this
systematic literature review due to access restrictions,
however, considering the great number of overlaps be-
tween Medline/EMBASE and Medline/PubMed, it is not
likely that any major study was left out of this review.
Also, we have chosen to include as many peer-reviewed
articles as possible, in this regard, a quality assessment
of included articles was not performed and methodo-
logically distinct studies were included. Our article selec-
tion strategy was based on the fact that systematic
reviews evaluate areas where evidence may be too het-
erogeneous for comparison and a meta-analysis study is
not possible [61, 62].
Conclusion
In conclusion, vitamin D deficiency is frequent in SSc
patients and seems to be associated with some clinical
and serological features of the disease. However, to date,
there is no evidence that the usual supplementation in-
terferes with vitamin D deficiency, and its clinical impact
remains uncertain. Further randomized trials on the
clinical effects of vitamin D supplementation are neces-
sary to verify the effects of vitamin D on the clinical
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characteristics of SSc, as well as to identify the potential
role of vitamin D on immunomodulation and treatment
of the disease. Thus, the optimal dosage of vitamin D
supplementation and the need for monitoring of 25(OH)
D serum levels in SSc patients are still open fields for re-
search. Further studies are also needed to clarify the re-
lationship between serum vitamin D levels and the
pathophysiology of SSc. It remains unclear if vitamin D
deficiency is an epiphenomenon or if it actually deter-
mines an increase in susceptibility and a worse prognosis
for this complex disease.
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